LBX Pharmacy (603883.SS): China Healthcare Corporate Day 2026 Takeaways

Research evidence excerpt

LBX Pharmacy (603883.SS): China Healthcare Corporate Day 2026 Takeaways

dising and store operations. Given the pharmacy

sector’s high operating leverage, with around 80% of costs being fixed, healthy

mature-store sales growth should translate into faster profit growth than revenue

growth. Franchise expansion and low-valuation acquisitions are also expected to

become more important growth driver from 2027 onward per management, while the

company’s improved operating cash flow provides additional flexibility for expansion.

Investment thesis

LBX Pharmacy is one of the leading retail pharmacy chain companies in China with a

footprint in 18 provinces. While we expect stable growth in the Pharmaceutical and

Healthcare Products market, we see LBX’s expansion capability as relatively weaker vs.

key peers, given its tighter cash position and its historical reliance on franchise-driven

store growth rather than M&A. As industry consolidation accelerates under polices

encouraging acquisitions, we believe companies with stronger balance sheets and

integration capabilities are better positioned to gain share. We forecast earnings CAGR

of c.15% in 2023-28E, but see limited upside at current levels given its relatively weaker

financial flexibility and expansion model. We therefore are Neutral rated. We see the

following as key catalysts in 2026: potential improvement in financial position, M&A

execution, and policy updates on non-drug sales.

Price Target Risks & Methodology

We are Neutral rated on LBX Pharmacy. Our 12-month TP is Rmb16, which is based on a

5-yr exit PE valuation, with WACC of 8.5% and exit PE at 18.2x. Downside risks: 1)

Stronger-than-expected impact from online competition; and 2) Slower policy

implementation or weaker-than-expected industry consolidation.